Cargando…
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome
PURPOSE: Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO(2)), and sleep architecture were...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098358/ https://www.ncbi.nlm.nih.gov/pubmed/20082240 http://dx.doi.org/10.1007/s11325-009-0320-0 |